Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations.

[1]  L. Babiuk,et al.  Efficacy of poly[di(sodium carboxylatophenoxy)phosphazene] (PCPP) as mucosal adjuvant to induce protective immunity against respiratory pathogens. , 2010, Vaccine.

[2]  R. Hancock,et al.  Synthetic Cationic Peptide IDR-1002 Provides Protection against Bacterial Infections through Chemokine Induction and Enhanced Leukocyte Recruitment , 2010, The Journal of Immunology.

[3]  L. Foster,et al.  Intracellular Receptor for Human Host Defense Peptide LL-37 in Monocytes1 , 2009, The Journal of Immunology.

[4]  L. Babiuk,et al.  A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. , 2009, Vaccine.

[5]  C. Siegrist.  The challenges of vaccine responses in early life: selected examples. , 2007, Journal of comparative pathology.

[6]  B. Morein,et al.  Immune responsiveness in the neonatal period. , 2007, Journal of comparative pathology.

[7]  Oreola Donini,et al.  An anti-infective peptide that selectively modulates the innate immune response , 2007, Nature Biotechnology.

[8]  R. Hancock,et al.  Cationic host defence peptides: Innate immune regulatory peptides as a novel approach for treating infections , 2007, Cellular and Molecular Life Sciences.

[9]  L. Babiuk,et al.  Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. , 2007, Vaccine.

[10]  R. Hancock,et al.  Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies , 2006, Nature Biotechnology.

[11]  R. Hancock,et al.  Peptide Antimicrobial Agents , 2006, Clinical Microbiology Reviews.

[12]  Cato T Laurencin,et al.  Effect of side group chemistry on the properties of biodegradable L-alanine cosubstituted polyphosphazenes. , 2006, Biomacromolecules.

[13]  Fiona S. L. Brinkman,et al.  Modulation of the TLR-Mediated Inflammatory Response by the Endogenous Human Host Defense Peptide LL-371 , 2006, The Journal of Immunology.

[14]  L. Babiuk,et al.  Immune Mechanisms and Therapeutic Potential of CpG Oligodeoxynucleotides , 2006, International reviews of immunology.

[15]  D. Klinman.  Adjuvant Activity of CpG Oligodeoxynucleotides , 2006, International reviews of immunology.

[16]  R. Hancock,et al.  Immunomodulatory Activities of Small Host Defense Peptides , 2005, Antimicrobial Agents and Chemotherapy.

[17]  Evelinda Trindade,et al.  Epidemiology of pertussis. , 2005, The Pediatric infectious disease journal.

[18]  D. Davidson,et al.  Impact of LL‐37 on anti‐infective immunity , 2005, Journal of leukocyte biology.

[19]  A. Andrianov,et al.  Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. , 2005, Biomacromolecules.

[20]  P. Lambert,et al.  Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. , 2004, Vaccine.

[21]  E. B. Lindblad.  Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[22]  K. Mills,et al.  Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen‐specific Th1 and enhancement of Th2, but not Tr1 cells , 2004, European journal of immunology.

[23]  L. Babiuk,et al.  Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[24]  D. Hoover,et al.  Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. , 2004, Annual review of immunology.

[25]  Robert E. W. Hancock,et al.  The Cationic Antimicrobial Peptide LL-37 Modulates Dendritic Cell Differentiation and Dendritic Cell-Induced T Cell Polarization1 , 2004, The Journal of Immunology.

[26]  P. Payette,et al.  Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities , 2004, European journal of immunology.

[27]  C T Laurencin,et al.  Biodegradable polyphosphazenes for drug delivery applications. , 2003, Advanced drug delivery reviews.

[28]  K. Mills.  Immunity to Bordetella pertussis. , 2001, Microbes and infection.

[29]  C. Siegrist.  Neonatal and early life vaccinology. , 2001, Vaccine.

[30]  K. Mills,et al.  Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. , 2000, The Journal of infectious diseases.

[31]  Andrianov,et al.  Protein release from polyphosphazene matrices. , 1998, Advanced drug delivery reviews.

[32]  K. Mills,et al.  A Murine Model in Which Protection Correlates with Pertussis Vaccine Efficacy in Children Reveals Complementary Roles for Humoral and Cell-Mediated Immunity in Protection againstBordetella pertussis , 1998, Infection and Immunity.

[33]  K. Mills,et al.  Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity , 1993, Infection and immunity.

[34]  K. Mills,et al.  Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model , 1993, Infection and immunity.

[35]  K. Bromberg,et al.  Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection , 1991, Infection and immunity.

[36]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[37]  W. Mitzner,et al.  Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease , 2009, Nature Medicine.

[38]  A. Galazka.  Control of pertussis in the world. , 1992, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[39]  Immunogenicity and Protective Efficacy of Neonatal Vaccination against Bordetella pertussis in a Murine Model: Evidence for Early Control of Pertussis , 2022 .